Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

• Status: Completed
• Trial end date: 2021-07-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Participants currently hospitalized for acute decompensated heart failure (ADHF)

• Participants must be hemodynamically stable, as assessed by the investigator

• Men must agree to follow specific methods of contraception, if applicable, while participating in the trial

• Women participants must have documented proof that they are not of childbearing potential

Exclusion Criteria:

• Acute cardiovascular condition other than heart failure (HF) decompensation

• Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization

• Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization

• Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis

Other protocol-defined inclusion/exclusion criteria apply